Table 1. Removal of NF-M/H tail domains protects against motor neuron degeneration in SOD1-mediated ALS in mice

## **Ventral (Motor) Root Axon Number (per L5 Root)**

| NF-(M/H) <sup>wild-type</sup> (control mice, at 14 m | NF-(M/H) <sup>tail∆</sup> onths and healthy) |                        | NF-(M/H) <sup>wild-type</sup><br>SOD1 <sup>G37R</sup> | NF-(M/H) <sup>tail∆</sup><br>SOD1 <sup>G37R</sup> | NF-M <sup>tail∆</sup><br>SOD1 <sup>G37R</sup> | NF-H <sup>tail∆</sup><br>SOD1 <sup>G37R</sup> |
|--|--|------------------------|---|---|---|---|
| 1008 ± 61 ( <i>n</i> =3)                             | $862 \pm 58 \ (n=4)$                         | presymptomatic:        | $1032 \pm 19 \ (n=3)$                                 | $862 \pm 78 \ (n=3)$                              | ND  | ND  |
|  |  | hind limb<br>weakness: | $517 \pm 29 \ (n=4)$                                  | $724 \pm 26 \ (n=3)$                              | $525 \pm 52 \ (n=3)$                          | $580 \pm 91 \ (n=2)$                          |
|  |  | end stage:             | $374 \pm 29 \ (n=4)$                                  | $613 \pm 51 \ (n=3)$                              | $384 \pm 33 \ (n=3)$                          | $460 \pm 31 (n=4)$                            |

## **Lumbar Ventral Horn Motor Neuron Number (per L3-L6 Section)**

| ${ m NF-(M/H)}^{ m wild-type} { m NF-(M/H)}^{ m tail\Delta}$ (control mice, at 14 months and healthy) |   |                                | NF-(M/H) <sup>wild-type</sup><br>SOD1 <sup>G37R</sup>                                      | NF-(M/H) <sup>tail∆</sup><br>SOD1 <sup>G37R</sup>   |  |
|---|---|--------------------------------|--|---|--|
| , ,   | $23 \pm 1.9 (n=3)^{1}$ $41 \pm 3.1 (n=3)^{2}$ pum diameter) | hind limb weakness: end stage: | $12 \pm 0.1 (n=3)^{1}$ $29 \pm 4.0 (n=3)^{2}$ $7 \pm 0.4 (n=3)^{1}$ $17 \pm 2.3 (n=3)^{2}$ | $18 \pm 0.4 (n=3)^{1}$ $36 \pm 0.2 (n=3)^{2}$ $12 \pm 0.5 (n=2)^{1}$ $28 \pm 5.5 (n=2)^{2}$ |  |

## **Percentage of Innervated End Plates in the Gastrocnemius Muscle**

| $NF$ - $(M/H)^{wild$ -type $NF$ - $(M/H)^{tail\Delta}$ (control mice, at 14 months and healthy) |    |                     | $rac{	ext{NF-(M/H)}^{	ext{wild-type}}}{	ext{SOD1}^{	ext{G37R}}}$ | NF-(M/H) <sup>tail∆</sup><br>SOD1 <sup>G37R</sup> |  |
|---|----|---------------------|---|---|--|
| $83 \pm 7.3 \ (n=3)$  | ND | hind limb weakness: | $26 \pm 2.2 (n=3)$  | $60 \pm 5.3 \ (n=3)$                              |  |
|   |    | end stage:          | $13 \pm 4.2 (n=3)$  | $25 \pm 5.9 (n=3)$                                |  |

Results are mean  $\pm$  SEM. Presymptomatic (at 6 months; before onset), hind limb weakness (at 10% weight loss; after onset), end stage (hind limb paralysis). Percentage of innervated end plates was determined as the fraction of bungarotoxin-positive endplates (postsynaptic) that were also positive for synaptophysin and NF (presynaptic). Per animal (n) 150 randomly choosen end plates were analyzed. ND, not determined.